<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN"
                           "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>Berlin/Heidelberg</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>268</JournalID>
      <JournalPrintISSN>0364-2313</JournalPrintISSN>
      <JournalElectronicISSN>1432-2323</JournalElectronicISSN>
      <JournalTitle>World Journal of Surgery</JournalTitle>
      <JournalAbbreviatedTitle>World J. Surg.</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</JournalSubject>
        <JournalSubject Code="SCH59001" Priority="1" Type="Secondary">Surgery</JournalSubject>
        <JournalSubject Code="SCH5901X" Priority="2" Type="Secondary">Abdominal Surgery</JournalSubject>
        <JournalSubject Code="SCH59028" Priority="3" Type="Secondary">Cardiac Surgery</JournalSubject>
        <JournalSubject Code="SCH59044" Priority="4" Type="Secondary">General Surgery</JournalSubject>
        <JournalSubject Code="SCH59095" Priority="5" Type="Secondary">Thoracic Surgery</JournalSubject>
        <JournalSubject Code="SCH59133" Priority="6" Type="Secondary">Vascular Surgery</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>22</VolumeIDStart>
        <VolumeIDEnd>22</VolumeIDEnd>
        <VolumeIssueCount>12</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>12</IssueIDStart>
          <IssueIDEnd>12</IssueIDEnd>
          <IssueHistory>
            <CoverDate>
              <Year>1998</Year>
              <Month>12</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>by the Société Internationale de Chirugie</CopyrightHolderName>
            <CopyrightYear>1998</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art1">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>4932</ArticleID>
            <ArticleDOI>10.1007/s002689900547</ArticleDOI>
            <ArticleSequenceNumber>7</ArticleSequenceNumber>
            <ArticleTitle Language="En">Genetic and Biochemical Screening for Endocrine Disease: III. Costs and Logistics</ArticleTitle>
            <ArticleFirstPage>1212</ArticleFirstPage>
            <ArticleLastPage>1217</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>1998</Year>
                <Month>3</Month>
                <Day>14</Day>
              </RegistrationDate>
              <OnlineDate>
                <Year>2014</Year>
                <Month>3</Month>
                <Day>14</Day>
              </OnlineDate>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>by the Société Internationale de Chirugie</CopyrightHolderName>
              <CopyrightYear>1998</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="A1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Leigh</GivenName>
                  <FamilyName>Delbridge</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="A2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Bruce</GivenName>
                  <FamilyName>Robinson</FamilyName>
                </AuthorName>
              </Author>
              <Affiliation ID="A1">
                <OrgName>Department of Surgery, Royal North Shore Hospital, St. Leonards 2065, New South Wales, Australia</OrgName>
                <OrgAddress>
                  <Country>Australia</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="A2">
                <OrgName>Department of Endocrinology, Royal North Shore Hospital, St. Leonards 2065, New South Wales, Australia</OrgName>
                <OrgAddress>
                  <Country>Australia</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="A3">
                <OrgName>Kolling Institute of Medical Research, Royal North Shore Hospital and University of Sydney, Sydney, New South Wales, Australia</OrgName>
                <OrgAddress>
                  <Country>Australia</Country>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>The cost of screening tests in endocrine disease can be determined in a number of ways, including the charge or billed cost, the production cost, or most appropriately the cost to achieve the intended aim of the test (cost-effectiveness). Cost-effectiveness analysis allows clinicians to determine whether an added benefit of a test comes at an acceptable cost. For example, analysis of the cost-effectiveness of routine thyroid function tests prior to surgery in elderly patients with nodular thyroid disease shows that the cost per life saved is only US $405, making the tests clearly cost-effective. Cost-effectiveness does not always equate with affordability, however, especially in developing countries. Thyroid function testing prior to surgery represents only 0.8% of the average household income in Australia and is therefore both cost-effective and affordable, whereas in Sri Lanka the same screening test represents up to 50% of the average monthly income. A survey of membership of the International Association of Endocrine Surgeons worldwide showed that molecular genetic screening for endocrine disease is readily available in 67% of institutions, with all of those having facilities for the rearrangement during transfection (
<Emphasis Type="Italic">RET</Emphasis>
                <Emphasis Type="Bold">) proto-oncogene testing, and lesser numbers having access to the </Emphasis>
                <Emphasis Type="Italic">Menin</Emphasis>
                <Emphasis Type="Bold">gene, the von Hippel-Lindau syndrome (</Emphasis>
                <Emphasis Type="Italic">VHL</Emphasis>
                <Emphasis Type="Bold">) gene, or linkage analysis for familial pheochromocytoma. The median cost of screening for the </Emphasis>
                <Emphasis Type="Italic">RET</Emphasis>
                <Emphasis Type="Bold"> proto-oncogene was $290 (range $100–3000). Cost-effectiveness analysis of molecular genetic screening for MEN-II syndrome demonstrates that the cost per life saved is only $5175. This compares favorably with reliance on screening based on annual pentagastrin testing, where the cost per life saved is as high as $76,315. Molecular genetic screening for endocrine disease (e.g., the MEN-II syndrome) is not only cost-effective but the therapy required (total thyroidectomy) is both acceptable and well tolerated.</Emphasis>
              </Para>
            </Abstract>
          </ArticleHeader>
          <NoBody/>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
